Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
CONCLUSION: We have developed a new practical adaptive dose-finding method to assess feasibility in early-phase adoptive cell therapy trials. A design that incorporates feasibility, as a function of the quantity and quality of the product manufactured, in addition to safety will have an impact on the recommended phase II doses in studies that evaluate patient outcomes.
PMID: 31856602 [PubMed - as supplied by publisher]
Source: Clinical Trials - Category: Research Authors: Wages NA, Fadul CE Tags: Clin Trials Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Research | Salaries | Study | Toxicology